Stockscreener 앱 받기
21.28
1.89%
-0.41
전일 마감가:
$21.69
열려 있는:
$21.67
하루 거래량:
135.30K
Relative Volume:
0.62
시가총액:
$1.46B
수익:
-
순이익/손실:
$-48.26M
주가수익비율:
-26.94
EPS:
-0.7899
순현금흐름:
$-45.04M
1주 성능:
+7.20%
1개월 성능:
+46.05%
6개월 성능:
+56.59%
1년 성능:
+90.34%
1일 변동 폭
$21.00
$21.94
1주일 범위
$18.89
$21.94
52주 변동 폭
$9.4557
$24.66
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
21.28 | 1.49B | 0 | -48.26M | -45.04M | -0.7899 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-13 | 개시 | Needham | Buy |
| 2025-06-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-13 | 개시 | Guggenheim | Buy |
| 2025-03-07 | 개시 | RBC Capital Mkts | Outperform |
| 2025-02-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-08-16 | 개시 | H.C. Wainwright | Buy |
| 2022-06-16 | 개시 | ROTH Capital | Buy |
모두보기
Gh Research Plc 주식(GHRS)의 최신 뉴스
Why (GHRS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
GH Research Raises $111 Million in Completed Share Offering to Fund Depression Pipeline - The Globe and Mail
GH Research (Nasdaq: GHRS) prices $117.5M underwritten share sale - Stock Titan
GH Research (GHRS) Expected to Announce Earnings on Thursday - MarketBeat
GH Research stock grabs retail spotlight ahead of FDA update on depression treatment - MSN
Gh Research announces pricing of $117.5 million underwritten offering - marketscreener.com
GH Research prices $117.5M share offering at $18 By Investing.com - Investing.com Canada
GH Research prices $117.5M share offering at $18 - Investing.com
GH Research (NASDAQ: GHRS) priced 6.53M-share offering at $18.00 - Stock Titan
Form 424B5 GH Research PLC - StreetInsider
GH Research Announces Pricing of $117.5 Million Underwritten Offering - The Manila Times
GH Research sells 6.5M shares at $18, raising $117.5M in U.S. offering - Stock Titan
Wall Street Analysts Think GH Research (GHRS) Could Surge 130.59%: Read This Before Placing a Bet - MSN
Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - MSN
A Look At GH Research (GHRS) Valuation After Recent Share Price Momentum - Sahm
GH Research Plc Statistics – TRADEGATE:1KA - TradingView
Total assets of GH Research Plc – TRADEGATE:1KA - TradingView
GH Research Plc Dividends – TRADEGATE:1KA - TradingView
1KA Stock Price and Chart — TRADEGATE:1KA - TradingView
Is GH (GHRS) stock cyclical or defensive | Q4 2025: Profit SurprisesAttention Driven Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On? - Sahm
Understanding Momentum Shifts in (GHRS) - Stock Traders Daily
GH Research stock hits 52-week high at $21.44 By Investing.com - Investing.com India
Psychedelic drug stocks are surging after Trump's order to fast-track development for medical use - Business Insider Africa
GH Research Up Nearly 22%, on Track for Highest Close Since January 2022 -- Data Talk - Moomoo
GH Research: WH Decision On Psychedelics To Treat Depression Makes Bull Case (NASDAQ:GHRS) - Seeking Alpha
GH Research stock hits 52-week high at $21.44 - Investing.com
These stocks are gapping in today's session - ChartMill
White House mental illness order aligns with GH Research's 2026 Phase 3 plan - Stock Titan
UPDATE 2-Psychedelic drug developers rally after Trump orders FDA to expedite reviews - Sahm
Florian Schonharting Net Worth (2026) - GuruFocus
Dermot John Hanley Net Worth (2026) - GuruFocus
GH Research PLC (NASDAQ:GHRS) Sees Large Decline in Short Interest - MarketBeat
Duncan Moore of GH Research (NASDAQ: GHRS) reports shares and vested options - Stock Titan
Magnus Clemensen Halle Net Worth (2026) - GuruFocus
Velichka Valcheva Net Worth (2026) - GuruFocus
Aaron Luke Cameron Net Worth (2026) - GuruFocus
Julie Ryan Net Worth (2026) - GuruFocus
Michael Forer Net Worth (2026) - GuruFocus
GH Research PLC (GHRS) Rating Update: A Biotech Stock With 121% Potential Upside - DirectorsTalk Interviews
GHRS Price Today: GH Research PLC Stock Price, Quote & Chart | MEXC - MEXC
GH Research PLC (NASDAQ:GHRS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Avoiding Lag: Real-Time Signals in (GHRS) Movement - Stock Traders Daily
Risk Off: Is GH Research PLC stock forming a cup and handle2026 Major Catalysts & Expert-Curated Trade Recommendations - baoquankhu1.vn
Risk Recap: Is GH Research PLC stock undervalued right now2026 Technicals & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Support Test: Is GH Research PLC a turnaround story2026 Volume Leaders & Stock Timing and Entry Methods - baoquankhu1.vn
GHRS SEC FilingsGh Research Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Here's Why We're Not At All Concerned With GH Research's (NASDAQ:GHRS) Cash Burn Situation - Yahoo Finance
Net current asset value per share of GH Research Plc – DUS:1KA - TradingView — Track All Markets
GH Research (NASDAQ: GHRS) COO details multiple share option grants - Stock Titan
GH Research PLC (GHRS) director details share and option holdings - Stock Titan
Gh Research Plc (GHRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):